98P Results from a phase I study of MK-1308 (anti –CTLA-4) plus pembrolizumab in previously treated advanced small cell lung cancer

ConclusionIn heavily pretreated pts with SCLC, MK-1308 + pembrolizumab was generally well tolerated with encouraging antitumor activity.Clinical trial identificationNCT03179436.Editorial acknowledgementMedical writing and/or editorial assistance was provided by Holly C. Cappelli, PhD, CMPP, and Dana Francis, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA) and funded by Merck Sharp& Dohme Corp, a subsidiary of Merck& Co., Inc., Kenilworth, NJ, USA.Legal entity responsible for the studyMerck Sharp and Dohme Corp., a subsidiary of Merck& Co., Inc., Kenilworth, NJ, USA.FundingMerck Sharp and Dohme Corp., a subsidiary of Merck& Co., Inc., Kenilworth, NJ, USA.DisclosureB.C. Cho: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Novartis; Honoraria (self), Research grant / Funding (self): Bayer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Honoraria (self), Research grant / Funding (self): MOGAM Institute; Honoraria (self), Research grant / Funding (self): Dong-A ST; Honoraria (self), Research grant / Funding (self), Licensing / Royalties: Champions Oncology; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Janssen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Yuhan; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Ono; Honoraria (self), Research grant / Funding (self): Diz...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research